Avalon Capital Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Avalon Capital Management’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-34,389	Closed	-$1.79M	–	89
2017 Q3	$1.79M	Sell	34,389 -759	-2%	-$39K	1.24%	27
2017 Q2	$1.82M	Sell	35,148 -33,132	-49%	-$1.67M	1.34%	29
2017 Q1	$3.44M	Buy	+68,280	New	+$3.38M	2.38%	11
2016 Q1	–	Sell	-37,479	Closed	-$2.02M	–	80
2015 Q4	$2.02M	Hold	37,479	–	–	1.82%	20
2015 Q3	$1.85M	Sell	37,479 -741	-2%	-$42.5K	1.7%	24
2015 Q2	$2.23M	Sell	38,220 -44,898	-54%	-$2.62M	2.03%	19
2015 Q1	$4.78M	Buy	83,118 +30,795	+59%	+$1.68M	3.86%	6
2014 Q4	$2.64M	Buy	52,323 +11,472	+28%	+$559K	2.03%	21
2014 Q3	$1.91M	Buy	40,851 +28,401	+228%	+$1.28M	1.59%	19
2014 Q2	$561K	Hold	12,450	–	–	0.47%	72
2014 Q1	$526K	Sell	12,450 -6,750	-35%	-$283K	0.43%	78
2013 Q4	$756K	Hold	19,200	–	–	0.64%	50
2013 Q3	$681K	Sell	19,200 -1,200	-6%	-$42.3K	0.67%	44
2013 Q2	$678K	Buy	+20,400	New	+$678K	0.67%	48

Other funds holding IHE

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AWA

ARS Wealth Advisors St. Petersburg, Florida $556M AUM 30.03% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Avalon Capital Management's IHE Position: Q4 2017 in Review

Avalon Capital Management sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2017, closing a stake of 34,389 shares — an estimated $1.79M sold.

Avalon Capital Management first reported a position in IHE in Q2 2013 and held it in 14 quarters. The position peaked at $4.78M in Q1 2015. 108 funds tracked by Wall St. Rank hold IHE as of Q4 2017.

Avalon Capital Management reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2017 after selling out during the quarter.
Avalon Capital Management sold 34,389 iShares US Pharmaceuticals ETF shares in Q4 2017, an estimated $1.79M.
Avalon Capital Management first reported a position in iShares US Pharmaceuticals ETF in Q2 2013 and held it in 14 quarters.
Avalon Capital Management's iShares US Pharmaceuticals ETF position peaked at $4.78M in Q1 2015.
108 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2017.

Based on Avalon Capital Management's 13F filing for Q4 2017, filed 26 Jan 2018.